Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2)

Journal of Cellular Physiology

Volumn 227, Issue 4, 2012, Pages 1529-1537

  Hampton, Philip J ^a   Jans, Ralph ^a   Flockhart, Ross J ^a   Parker, Graeme ^a   Reynolds, Nick J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT2; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SUBSTRATE; EPIDERMIS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; KERATINOCYTE; LYMPHOCYTE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS; SKINFOLD THICKNESS; TRANSCRIPTION INITIATION;

BASE SEQUENCE; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KERATINOCYTES; LITHIUM; NFATC TRANSCRIPTION FACTORS; PSORIASIS; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 84855719836     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22872     Document Type: Article

References (65)

1. Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. 2002. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 118:779-788.
2. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. 1997a. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275:1930-1934.
3. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. 1997b. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275:1930-1934.
4. Beurel E, Michalek SM, Jope RS. 2010. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 31:24-31.
5. Bhat RV, Budd Haeberlein SL, Avila J. 2004. Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 89:1313-1317.
6. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199:731-736.
7. Buchholz M, Ellenrieder V. 2007. An emerging role for Ca2+/calcineurin/NFAT signaling in cancerogenesis. Cell Cycle 6:16-19.
8. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80:273-290.
9. Chuvpilo S, Jankevics E, Tyrsin D, Akimzhanov A, Moroz D, Jha MK, Schulze-Luehrmann J, Santner-Nanan B, Feoktistova E, Konig T, Avots A, Schmitt E, Berberich-Siebelt F, Schimpl A, Serfling E. 2002. Autoregulation of NFATc1/A expression facilitates effector T cells to escape from rapid apoptosis. Immunity 16:881-895.
10. Cui H, Meng Y, Bulleit RF. 1998. Inhibition of glycogen synthase kinase 3beta activity regulates proliferation of cultured cerebellar granule cells. Brain Res Dev Brain Res 111:177-188.
11. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, Giardina E, Stuart PE, Nair R, Helms C, Escaramis G, Ballana E, Martin-Ezquerra G, den Heijer M, Kamsteeg M, Joosten I, Eichler EE, Lazaro C, Pujol RM, Armengol L, Abecasis G, Elder JT, Novelli G, Armour JA, Kwok PY, Bowcock A, Schalkwijk J, Estivill X. 2009. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 41:211-215.
12. Di Cesare A, Di Meglio P, Nestle FO. 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339-1350.
13. Farr GH III, Ferkey DM, Yost C, Pierce SB, Weaver C, Kimelman D. 2000. Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J Cell Biol 148:691-702.
14. Ferkey DM, Kimelman D. 2002. Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. J Biol Chem 277:16147-16152.
15. Fisher GJ, Duell EA, Nickoloff BJ, Annesley TM, Kowalke JK, Ellis CN, Voorhees JJ. 1988. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol 91:142-146.
16. Franca-Koh J, Yeo M, Fraser E, Young N, Dale TC. 2002. The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. J Biol Chem 277:43844-43848.
17. Gaspari AA. 2006. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 54:S67-S80.
18. Goodwin P, Hamilton S, Fry L. 1973. A comparison between DNA synthesis and mitosis in uninvolved and involved psoriatic epidermis and normal epidermis. Br J Dermatol 89:613-618.
19. Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, Ghosh D, Aphale A, Gumucio DL, Voorhees JJ, Abecasis GR, Elder JT. 2009. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 129:2795-2804.
20. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B, Burger PC, Wood PA, Taqi F, Booker SV, Petersen GM, Offerhaus JA, Tersmette AC. Giardiello FM, Volgelstein B, Kinzler KW. 1995. The molecular basis of Turcot's syndrome. N Engl J Med 332:839-847.
21. Happle R. 1991. Somatic recombination may explain linear psoriasis. J Med Genet 28:337.
22. Hatta N, Takata M, Kawara S, Hirone T, Takehara K. 1997. Tape stripping induces marked epidermal proliferation and altered TGF-alpha expression in non-lesional psoriatic skin. J Dermatol Sci 14:154-161.
23. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. 1997. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action. Dev Biol 185:82-91.
24. Hedin KE, Bell MP, Kalli KR, Huntoon CJ, Sharp BM, McKean DJ. 1997. Delta-opioid receptors expressed by Jurkat T cells enhance IL-2 secretion by increasing AP-1 complexes and activity of the NF-AT/AP-1-binding promoter element. J Immunol 159:5431-5440.
25. 3H-thymidine by epidermal cells in normal and psoriatic subjects. DNA synthesis in psoriasis. Br J Dermatol 78:262-268.
26. Horsley V, Aliprantis AO, Polak L, Glimcher LH, Fuchs E. 2008. NFATc1 balances quiescence and proliferation of skin stem cells. Cell 132:299-310.
27. Huffmeier U, Bergboer JG, Becker T, Armour JA, Traupe H, Estivill X, Riveira-Munoz E, Mossner R, Reich K, Kurrat W, Wienker TF, Schalkwijk J, Zeeuwen PL, Reis A. 2010. Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Invest Dermatol 130:979-984.
28. Hui W, Litherland GJ, Jefferson M, Barter MJ, Elias MS, Cawston TE, Rowan AD, Young DA. 2010. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology (Oxford) 49:2043-2053.
29. Jans R, Sturniolo MT, Eckert RL. 2008. Localization of the TIG3 transglutaminase interaction domain and demonstration that the amino-terminal region is required for TIG3 function as a keratinocyte differentiation regulator. J Invest Dermatol 128:517-529.
30. Jonkers J, Korswagen HC, Acton D, Breuer M, Berns A. 1997. Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. EMBO J 16:441-450.
31. Jope RS, Johnson GV. 2004. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95-102.
32. Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, Eldar-Finkelman H. 2004. Lithium-mediated phosphorylation of glycogen synthase kinase-3b involves PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosci 24:237-245.
33. Lipskaia L, Lompre AM. 2004. Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation. Biol Cell 96:55-68.
34. Lyakh L, Ghosh P, Rice NR. 1997. Expression of NFAT-family proteins in normal human T cells. Mol Cell Biol 17:2475-2484.
35. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. 1999. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: Therapeutic implications. J Clin Psychiatry 60:27-39. Discussion 40-21, 113-116.
36. Martin M, Rehani K, Jope RS, Michalek SM. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777-784.
37. McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. 2005. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 19:1012-1014.
38. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P. 2003. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10:1255-1266.
39. Murphy LL, Hughes CC. 2002. Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: Involvement of the wnt/glycogen synthase kinase-3 beta pathway. J Immunol 169:3717-3725.
40. Neal JW, Clipstone NA. 2001. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. J Biol Chem 276:3666-3673.
41. Nestle FO, Kaplan DH, Barker J. 2009. Psoriasis. N Engl J Med 361:496-509.
42. Ohteki T, Parsons M, Zakarian A, Jones RG, Nguyen LT, Woodgett JR, Ohashi PS. 2000. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 192:99-104.
43. Oliver JE, Silman AJ. 2009. What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther 11:223.
44. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, de Ridder D, Kupka RW, Nolen WA, Drexhage HA. 2008. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 65:395-407.
45. Park KW, Yang HM, Youn SW, Yang HJ, Chae IH, Oh BH, Lee MM, Park YB, Choi YS, Kim HS, Walsh K. 2003. Constitutively active glycogen synthase kinase-3beta gene transfer sustains apoptosis, inhibits proliferation of vascular smooth muscle cells, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 23:1364-1369.
46. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. 2006. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 176:1908-1915.
47. Poumay Y, Dupont F, Marcoux S, Leclercq-Smekens M, Herin M, Coquette A. 2004. A simple reconstructed human epidermis: Preparation of the culture model and utilization in in vitro studies. Arch Dermatol Res 296:203-211.
48. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. 2010. Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol 9:727-739.
49. Regl G, Neill GW, Eichberger T, Kasper M, Ikram MS, Koller J, Hintner H, Quinn AG, Frischauf AM, Aberger F. 2002. Human GLI2 and GLI1 are part of a positive feedback mechanism in basal cell carcinoma. Oncogene 21:5529-5539.
50. Ryves WJ, Harwood AJ. 2001. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280:720-725.
51. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11:43-49.
52. Santini MP, Talora C, Seki T, Bolgan L, Dotto GP. 2001. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA 98:9575-9580.
53. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. 2004. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10:55-63.
54. Serfling E, Chuvpilo S, Liu J, Hofer T, Palmetshofer A. 2006. NFATc1 autoregulation: A crucial step for cell-fate determination. Trends Immunol 27:461-469.
55. Shen F, Li N, Gade P, Kalvakolanu DV, Weibley T, Doble B, Woodgett JR, Wood TD, Gaffen SL. 2009. IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal 2:ra8.
56. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
57. Skoven I, Thormann J. 1979. Lithium compound treatment and psoriasis. Arch Dermatol 115:1185-1187.
58. Todd C, Reynolds NJ. 1998. Up-regulation of p21WAF1 by phorbol ester and calcium in human keratinocytes through a protein kinase C-dependent pathway. Am J Pathol 153:39-45.
59. Turner H, Gomez M, McKenzie E, Kirchem A, Lennard A, Cantrell DA. 1998. Rac-1 regulates nuclear factor of activated T cells (NFAT) C1 nuclear translocation in response to Fcepsilon receptor type 1 stimulation of mast cells. J Exp Med 188:527-537.
60. Vines A, Cahoon S, Goldberg I, Saxena U, Pillarisetti S. 2006. Novel anti-inflammatory role for glycogen synthase kinase-3beta in the inhibition of tumor necrosis factor-alpha- and interleukin-1beta-induced inflammatory gene expression. J Biol Chem 281:16985-16990.
61. Voigt W. 2005. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110:39-48.
62. Welsh GI, Proud CG. 1993. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 294:625-629.
63. Wolf R, D'Avino M, De Angelis F, Ruocco E, Lombardi ML. 2000. Effects of lithium carbonate (Li2CO3) on in-vitro-cultured normal human skin explants. J Eur Acad Dermatol Venereol 14:97-99.
64. Yost C, Farr GH III, Pierce SB, Ferkey DM, Chen MM, Kimelman D. 1998. GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 93:1031-1041.
65. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-651.